Search

everythinglearnresearchcommunity

for

Search:↓

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

A Rathke's cleft cyst caused hormonal imbalances and symptoms in a 68-year-old woman.

Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.

THAP1 gene changes do not affect DYT1 dystonia; finasteride may help reduce tics and OCD in Tourette syndrome.

Long-standing benign tumors can become cancerous, especially in people with weakened immune systems.

Androgen receptors are found in some skin tumors but not in hair follicle tumors.

Tay syndrome is a unique genetic disorder causing skin, hair, and developmental issues.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Skin changes like dryness and hair loss can signal hypothyroidism before tests confirm it.

Alopecia areata is an autoimmune disease that targets hair follicles.

Mutations in the glucocorticoid receptor gene cause reduced sensitivity to glucocorticoids and may lead to poor response to treatment.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.

All-trans retinoic acid causes hair loss by increasing TGF-β2 in hair follicle cells.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

IFN-γ production by CD4 T cells is crucial for causing alopecia areata.

TNF-a may not be as involved in certain types of hair loss as previously thought.

JAK inhibitors are effective treatments for alopecia areata.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Consider TFI in facial hypopigmentation diagnoses and confirm with a biopsy.

A specific gene variant (rs4833095) is linked to a higher risk of alopecia areata in Koreans.

The study found that analyzing certain cell signaling pathways is not a reliable method to tell apart two types of skin tumors.

Removing the thymoma improved the patient's alopecia areata, suggesting a possible link between the two.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Consider THPP in patients with muscle weakness and low potassium, as it is often underdiagnosed.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.